BR0314529A - Polipeptìdeos de papilomavìrus humano e composições imunogênicas - Google Patents

Polipeptìdeos de papilomavìrus humano e composições imunogênicas

Info

Publication number
BR0314529A
BR0314529A BR0314529-8A BR0314529A BR0314529A BR 0314529 A BR0314529 A BR 0314529A BR 0314529 A BR0314529 A BR 0314529A BR 0314529 A BR0314529 A BR 0314529A
Authority
BR
Brazil
Prior art keywords
immunogenic
fusions
immunogenic compositions
hpv
human papillomavirus
Prior art date
Application number
BR0314529-8A
Other languages
English (en)
Inventor
Larry Smith
Maria Cristina Cassetti
Susan P Mcelhiney
Jeffrey K Pullen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0314529A publication Critical patent/BR0314529A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"POLIPEPTìDEOS DE PAPILOMAVìRUS HUMANO E COMPOSIçõES IMUNOGêNICAS". A presente invenção fornece composições imunogênicas e farmacêuticas para o tratamento e prevenção de cânceres associados com o papilomavírus humano (HPV) e em particular, câncer cervical. Em particular, esta invenção refere-se às proteínas de fusão, e aos ácidos nucléicos codificando estas proteínas de fusão, empregadas para gerar respostas imunes contra HPV. Especificamente, esta invenção provê fusões de E6 e E7 de HPV nas quais E6 e/ou E7 contêm uma ou mais mutações. Estas mutações ab-rogam a atividade de transformação destas proteínas oncogênicas e, desse modo, conferem segurança às fusões E6/E7. Além disso, estas fusões mantêm ou aumentam a eficácia imunogênica de E6 e E7. Qualquer método de liberação de gene ou proteína pode ser empregado para liberar ou embalar as composições imunogênicas da presente invenção.
BR0314529-8A 2002-10-03 2003-10-02 Polipeptìdeos de papilomavìrus humano e composições imunogênicas BR0314529A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41592902P 2002-10-03 2002-10-03
PCT/US2003/031726 WO2004030636A2 (en) 2002-10-03 2003-10-02 Human papillomavirus polypeptides and immunogenic compositions

Publications (1)

Publication Number Publication Date
BR0314529A true BR0314529A (pt) 2005-08-09

Family

ID=32069921

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314529-8A BR0314529A (pt) 2002-10-03 2003-10-02 Polipeptìdeos de papilomavìrus humano e composições imunogênicas

Country Status (16)

Country Link
US (2) US7223408B2 (pt)
EP (1) EP1553966B1 (pt)
JP (2) JP4755422B2 (pt)
KR (1) KR101145190B1 (pt)
CN (1) CN1720060B (pt)
AU (1) AU2003282731B2 (pt)
BR (1) BR0314529A (pt)
CA (1) CA2499837C (pt)
CO (1) CO5700784A2 (pt)
DK (1) DK1553966T3 (pt)
ES (1) ES2391451T3 (pt)
MX (1) MXPA05003395A (pt)
NZ (1) NZ556544A (pt)
PT (1) PT1553966E (pt)
WO (1) WO2004030636A2 (pt)
ZA (1) ZA200502618B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
ES2454640T3 (es) 2000-08-03 2014-04-11 Johns Hopkins University Vacuna molecular que lleva unida un polipéptido de chaperona del retículo endoplasmático a un antígeno
KR101145190B1 (ko) * 2002-10-03 2012-05-14 와이어쓰 홀딩스 코포레이션 사람 파필로마바이러스 폴리펩타이드 및 면역원성 조성물
EP1644048B1 (en) 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US8399610B2 (en) * 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
GB0417430D0 (en) * 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
JP4474264B2 (ja) 2004-08-20 2010-06-02 生寶生物科技股▲ふん▼有限公司 子宮頸癌抑制の融合蛋白
ATE476528T1 (de) 2004-12-08 2010-08-15 Gen Probe Inc Nukleinsäuredetektion aus verschiedenen typen des humanen papillomavirus
CA2594040A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
CA2594771A1 (en) 2005-01-14 2006-07-20 The Regents Of The University Of Michigan Systems, methods, and compositions for detection of human papilloma virus in biological samples
EP1846026A4 (en) * 2005-01-26 2008-07-02 Univ Johns Hopkins ANTICANCER DNA VACCINE USING PLASMID CODING ANTIGEN AND CALRETICULIN SUCH AS MUTANT ONCOPROTEINS
US8137674B2 (en) * 2006-04-19 2012-03-20 Postech Foundation Compositions comprising HPV polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US8222214B2 (en) * 2007-06-01 2012-07-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse
US20090117123A1 (en) * 2007-11-02 2009-05-07 National Health Research Institutes Immunopeptides of hpv e6 and e7 proteins
US20120121715A1 (en) * 2008-01-02 2012-05-17 National Taiwan University DNA Vaccine Comprising IL-6-Encoding DNA Construct and Applications Thereof
EP2335730A1 (en) * 2009-12-18 2011-06-22 Deutsches Krebsforschungszentrum Fusion polypeptides and their use for prevention and treatment of cancer
KR101197627B1 (ko) * 2010-01-18 2012-11-07 (주)레퍼런스바이오랩 Ｈｐｖ 감염과 관련된 암의 치료용 조성물
CA2789456C (en) * 2010-02-16 2017-11-21 Becton, Dickinson And Company Assay for detecting closely-related serotypes of human papillomavirus (hpv)
AU2011258501B2 (en) 2010-05-25 2016-07-07 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
CN103180343B (zh) * 2010-08-13 2016-01-20 株式会社吉耐森 用于预防或治疗宫颈癌的、包含人乳头瘤病毒变形体及免疫增强剂的组合物
EP3443982A1 (en) * 2011-10-12 2019-02-20 The Trustees of the University of Pennsylvania Vaccines for human papilloma virus and methods for using the same
DK2793937T3 (da) 2011-12-21 2019-07-01 Vaccibody As Vacciner mod HPV
ES2646590T3 (es) * 2012-01-24 2017-12-14 Sanford Health Polinucleótidos para el tratamiento de tumores positivos para polipéptidos víricos oncogénicos
CN103288931B (zh) * 2012-02-24 2015-05-27 宋硕 人类乳头瘤病毒免疫原性多肽、其制备方法及应用
EA034056B1 (ru) * 2013-03-12 2019-12-23 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Усовершенствованные вакцины против вируса папилломы человека и способы их применения
CN107073070A (zh) 2014-08-15 2017-08-18 格纳西尼有限公司 治疗宫颈癌的方法
JP5973007B2 (ja) * 2015-01-30 2016-08-17 ジェネクサイン・インコーポレーテッド ヒトパピローマウイルス変形体及び免疫増強剤を含む子宮頸癌の予防または治療用組成物
DK3283508T3 (en) * 2015-04-17 2021-05-31 Alpine Immune Sciences Inc Immunomodulatory Proteins with Tunable Affinities
WO2016198531A2 (en) * 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
PT3359183T (pt) * 2015-10-06 2020-08-13 Invectys Construções de poliepítopo para utilização em imunoterapia
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
CN106632694B (zh) * 2017-01-24 2021-02-12 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
EP3606549A1 (en) * 2017-04-07 2020-02-12 Hookipa Biotech GmbH Arenavirus particles to treat solid tumors
EP3461497A1 (en) 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
US20220334132A1 (en) * 2019-08-08 2022-10-20 The Trustees Of Indiana University Methods for identifying and treating urinary tract infections
PE20231054A1 (es) 2020-04-24 2023-07-11 Genexine Inc Metodo para tratamiento del cancer cervicouterino
CN114478712B (zh) * 2022-03-29 2022-09-23 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
AUPN443995A0 (en) 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CN1433428A (zh) * 2000-04-05 2003-07-30 冲击诊断公司 辨别人乳头瘤病毒的免疫学方法
KR101145190B1 (ko) * 2002-10-03 2012-05-14 와이어쓰 홀딩스 코포레이션 사람 파필로마바이러스 폴리펩타이드 및 면역원성 조성물

Also Published As

Publication number Publication date
MXPA05003395A (es) 2005-06-22
JP5398665B2 (ja) 2014-01-29
US20060014926A1 (en) 2006-01-19
ZA200502618B (en) 2008-10-29
CO5700784A2 (es) 2006-11-30
PT1553966E (pt) 2012-10-22
EP1553966A4 (en) 2008-04-16
CA2499837C (en) 2013-12-03
JP2010279386A (ja) 2010-12-16
CA2499837A1 (en) 2004-04-15
EP1553966B1 (en) 2012-08-01
DK1553966T3 (da) 2012-09-17
WO2004030636A2 (en) 2004-04-15
US7223408B2 (en) 2007-05-29
JP2006501825A (ja) 2006-01-19
KR20050053732A (ko) 2005-06-08
AU2003282731A1 (en) 2004-04-23
US20070275003A1 (en) 2007-11-29
CN1720060B (zh) 2011-12-14
US7378099B2 (en) 2008-05-27
NZ556544A (en) 2008-11-28
CN1720060A (zh) 2006-01-11
WO2004030636A3 (en) 2005-02-24
ES2391451T3 (es) 2012-11-26
AU2003282731B2 (en) 2009-01-08
EP1553966A2 (en) 2005-07-20
KR101145190B1 (ko) 2012-05-14
JP4755422B2 (ja) 2011-08-24

Similar Documents

Publication Publication Date Title
BR0314529A (pt) Polipeptìdeos de papilomavìrus humano e composições imunogênicas
BR0007840A (pt) Proteìnas de fusão her-2/neu
EP1427744A4 (en) ANTIBODY EXPRESSION SYSTEM AND ASSEMBLY
CY1114265T1 (el) Πρωτεϊνη συντηξης αλβουμινης
AU2002305450A1 (en) Proteomimetic compounds and methods
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2002060955A3 (en) Modified antibodies and methods of use
TNSN08064A1 (en) Albumin fusion proteins
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
AU3368497A (en) Human dnase i hyperactive variants
HUP0400231A2 (hu) Rákos megbetegedések kezelésében különösen hasznos, immundecepcióra szolgáló eljárások és gyógyszerkészítmények
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
AU2001254624A1 (en) Human coagulation factor vii variants
BRPI0507026A (pt) proteìnas de fusão de albumina
EP4249064A3 (en) Novel fusion protein specific for cd137 and pd-l1
NZ711567A (en) Antibody formulations
MX2021010039A (es) Novedosas proteinas de fusion especificas para cd137 y gpc3.
NO20055209L (no) Peptabody for cancerbehandling
BR0207819A (pt) Proteìna, citocina, il-13 humano mutado, polinucleotìdeo, vetor, hospedeiro, composição farmacêutica, uso de uma proteìna, métodos para o tratamento de profilaxia de doença mediada por il-13, e para a preparação de uma proteìna
BR0208041A (pt) Interferon beta modificado com imunogenicidade reduzida
ZA200108414B (en) Akt nucleic acids, polypeptides, and uses thereof.
MY134288A (en) Composition and its therapeutic use
PL1636261T3 (pl) Białka trombopoetynowe o ulepszonych właściwościach
WO2023049636A3 (en) Cancer therapy compositions and uses thereof
WO2004031354A3 (en) Human sarcoma-associated antigens

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL